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Ganglioside GM3 is the predominant ganglioside ofkeratino-
eyte m.embranes. It has been prop~sed in other c~ll tyl?es that 
GM3 m.ay participate in th~ regulat.lOn of ce ll pr.ohfe~atlon. T.o 
exam.ine the role of GM3 m keratmocyte prohferatlOn, pun-
fied G M3 was added to cultured keratinocytes from normal 
foreskin, from lesional skin of patients with psoriasis and 
ichthyosis, and to cutaneous squamous carcinoma cell lines. 
Supplemental GM3 inhibited the growth of all cultured. kerati-
nocytes in a dose-dependent manner at concentratlons of 
10- 100 ,uM. Keratinocytes from patients with psoriasis and 
ichth yosis were most sensitive to the inhibitory effects of 
GM3 , and confluent undifferentiated keratinocytes were least 
G angliosides are sialylated glycosphingolipids that are predominantly located in the plas.ma membrane. Al-terations in gangltoslde metaboltsm have been ob-served during density-dependent growth inhibition and oncogenic transformation [1,2] suggesting that 
gangliosides may parti.cipate .in the re~ul~tion of cell proliferation. 
In fact, sphingolipids, 1\1clud1\1g ganghoslde GM3 , have been shown 
to be potent ,rharmacologic regulators of cell prol~ferati?n and dif-
ferentiation l2,3] probably through direct 1\1teractlon with growth 
factor receptors [3 -5].. . . . . 
Gangliosides comprISe 0.1 % of the Itplds of e~lde~ml~, and 65% 
of the ganglioside of kerat1110cyte membranes III 111110 IS GM3 [6] . 
Monoclonal antibodies directed against G M3 bind strongly to the 
stratum corneum of normal epidermis, but binding is decreased or 
absent in many disorders of epidermal hyperproliferation, including 
psoriasis, squamous c~ll carcinoma (SCC), and the. h~perprolifera­
tive forms of ichthyosIs [7]. Furthermore, the ganghoslde content of 
tissue from both nodular and sclerosing basal cell carcinomas differs 
from that of normal keratinocytes ill VillO, with a markedly increased 
overall ganglioside content and a significant concentration of 9-0-
acetyl-Go3 [6]. These observations suggest that gangliosides, partic-
ularly G M3 and 9-0-acetyl-Go3 , may playa role in the regulation of 
proliferation of keratinocytes. The purpose of the experiments 
presented here was to examine the pharm.acologi~ effect of ganglio-
sides on keratinocyte proltferatlon and differentiatIOn. 
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NANA, N-acerylneuranul1lc aCId; ST-II, s!alyltransferase II. 
sensitive. No change in differentiation was noted after addi-
tion of GM3 · GD3 , 9-0-acetyl-GD3 , and GDlb also inhibited 
keratinocyte proliferation. Gangliosides GM1 and GDb and 
sialic acid had little effect. Addition of 50,uM 3H-GM3 to 
cultured keratinocytes resulted in 1.7 times the amount of 
cellular GM3 . These data suggest that hematoside (GM3) and 
"b" pathway gangliosides (GD3 , GD1b), generated by the pref-
erential activation of sialyltransferase II versus N-acetylga-
lactosaminyltransferase, may be involved in control ofkerati-
nocyte growth but not of differentiation. ] Invest Dermatol 
100:841-845, 1993 
MATERIALS AND METHODS 
Materials High-performance thin-layer chromatography 
(HPTLC) plates were from Merck (Darmstadt, Germany); rabbit 
polyclonal antibodies were provided as follows: anti-desmoplakin 
antibody by Dr. K. Greene (Chicago, IL) and anti-involucrin anti-
body from Biomedical Technologies, Inc. (Stoughton, MA). Gan-
glioside standards for HPTLC plates were used without purification 
and purchased as follows: GM2 from Boehringer-Mallnheim (India-
napolis, IN); G03 from Genzyme (Boston, MA);Gol. , GOlb ' GTlb , 
and sialic acid from Sigma (St. Louis, MO). For addition to cultures, 
GMI , GM3 , GD3 , Got., and 9-0-acetyl-GD3 were prepared and puri-
fied fully as described below; these gangliosides were used as stan-
dards without fu ll purification. GOlb (Sigma, St. Louis, MO) was 
further purified by HPLC before addition to cultures. 
Cells and Culture of Keratinocytes Keratinocytes from dis-
carded normal foreskin and lesional sk in from patients with psoria-
sis and ichthyosis, biopsied after informed consent, were seeded in 
complete serum-free keratinocyte growth medium (KGM, Clone-
tics Corp., San Diego, CA) [8], with low calcium (0.07 mM or 
0.15 mM) or high calcium (1.5 m.M) concentration. Cutaneous 
squamous cell carcinoma (SCC) lines SCC-12B2, SCC-12F2, and 
SCC-13 (courtesy of Dr. James Rheinwald, Boston, MA) [9] were 
initiated in 75% Dulbecco's minimum essential medium with 25% 
Ham's F-12 and 20% fetal calf serum and subsequently grown in 
KGM as for keratinocytes. 
Purification of Gangliosides for Treatment of Cultured 
Cells Gangliosides GM3 , GMI , and GOI., GO), and 9-0-acetyl-GO) 
were extracted from dog erythrocytes [7,10], bovine brain [11], 
SK-MEL-28 melanoma cells (American Type Culture Collecti?n), 
and trout liver [12] , respectively, and prepared from the total hpld 
extracts with chloroform: methanol as previously described [7] . 
Gangliosides were quantitiated by dry weight and colorimetric re-
sorcinol assays [13]. 
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Figure 1. Effect of gangliosides on proliferation of normal and neoplastic keratinocytes. Cultured keratinocytes were treated with gangliosides at 24 and 72 h 
after initiation, counted by 24-h JH-thymidine labeling and harvested on day 6. Error bars, SEM in a and SO in all other figures. a, effect of G J, GMt' 
9-0-acetyl-GD3 , GD3 , sialic acid (NANA), Got., and GOtb on normal keratinocytes grown in 0.15 mM Ca++ KGM. Control cell numbers = 1.27 MX 106 ± 
0.29 X 106 cell s. Forthe various ganglioside inhibitory curves, number of runs were NANA, n = 3; GMt' n = 18; GOt" n = 9; GOtb ' n = 9; GOJ , n = 6; GMJ, 
n = 30; 9-0-acetyl-GoJ , n = 9. b, effect of GMJ and GMt on keratinocytes grown in 1.5 mM Ca++ KGM. Control cell numbers = 0.71 X 106 ± 0.07 X 106 
cells; SCC lines treated with GMt were grown in 0.15 mM Ca++, whereas cells treated with GMJ were grown at 0.15 mM Ca++ (Le) or 1.5 111M Ca++ (He). c, 
SCC-12F2. Control cell numbers = 0.92 X 106 ± 0.10 X 106 cells. d, SCC-B. Control cell numbers = 1.43 X 106 ± 0.19 X 106 cells. 
Addition of Ganglioside to Cultured Keratinocytes Nor-
mal, psoriatic, and ichthyotic keratinocytes were seeded at a density 
of 5 X 103 cells/ml in 0.15 mM Ca++ and 5 X 104 for growth in 
1.5 mM Ca++ KGM. SCC lines were seeded at a density of 5 X 103 
cel ls/well for growth in 0.15 mM Ca++ and at 2.5 X 104 cells/well 
for growth in 1.5 mM Ca++ KGM. The GM3 , GM1 , GOla ' G01b ' 
G03, 9-0-acetyl-Go3 , and sialic acid were added as described by 
Bremer et at [3J to keratinocytes in second or third passage or to the 
SCC lines in 24-well flat-bottomed plates at final concentrations of 
1 - 100 J.lM, with at least triplicate cultures at each concentration. 
Gangliosides were added on day 2 and subsequently every other day 
with feeding until the cultured cells were harvested (day 6 for pre-
confluent and day 12 for post-confluent cells). KGM medium with-
out gangliosides was added to control cultures whenever ganglio-
side was added to treated cultures. The time course of the effect of 
gangliosides was determined by assessment of cell proliferation 
daily during the course of study. To study the reversibility ofinhibi-
tion of proliferation by GM3 , keratinocytes were incubated with or 
without GM3 for 72 h; cells treated with GM3 were subsequently 
washed and grown in KGM medium without GM3 for 12 - 72 h. All 
experiments were repeated at least three times. Keratinocytes from 
10 patients with plaque-type psoriasis were studied; the ichthyotic 
keratinocytes were from patients with non-bullous congenital 
ichthyosiform erythroderma (n = 2) and bullous congenital ichthy-
osiform erythroderma (n = 1). 
Proliferation Assays For preconfluent cultures, 1 ).lCi/ml 3H_ 
thymidine (specific activity 25 Ci/mmol, Amersham Corp., Ar-
lington Heights, IL) was added and incubated with cells for 24 h 
before harvesting [14]. Radioactivity was counted in a scintillation 
counter (TmAnalytic model 6892). For studies of post-confluent 
cells, 4 J.lCi/ml of methyPH-thymidine was added and keratino-
cytes were harvested 2 h later, owing to the catabolism of thymi-
dine by post-confluent keratinocytes [15J. Cellular proliferation 
was also assessed by counting cells with a hemacytometer. Counting 
by hemacytometer correlated well with counting by 3H-thymidine 
labeling. Cell viability was determined by trypan blue exclusion of 
harvested cells, as well as of non-adherent cells collected before 
feeding and harvesting. Counting was performed in triplicate. 
Detection of Differentiation The effect of supplemental gan-
gliosides on cel lular differentiation was assessed by cornified enve-
lope formation, and ce ll morphology by light microscopy and the 
alteration in immunostaining with antibodies against desmoplakin 
and involucrin. The number of cornified envelopes was measured 
by resistance to lysis by detergent in the presence of reducing agent, 
as described by Rice and Green [16]. Measurements of cornified 
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envelope formation were performed in triplicate. Immunofluores-
cent studies with rabbit anti-human desmoplakin antibody (17) and 
rabbit anti-human involucrin antibody [18] followed routine immu-
nofluorescent techniques [19)' with keratinocytes grown to pre-
confluence in KGM medium with 0.07 mM or 1.5 mM calcium. 
Radiolabeling of G M1 Purified GM3 was labeled at the ceramide 
moiety with 3H-NaBH4 (specific activity 60 Ci/mmol, American 
Radiolaheled Chemicals, Inc., St. Louis, MO) and palladium by the 
method of Schwarzmann (20) to provide a product that is stable to 
the in vivo action of neuraminidase. The 3H-labeled GM3 was ana-
lyzed by HPTLC, resorcinol detection of ganglioside bands and 
development by autoradiography. Specific radioactivity of known 
amounts ofGM1 was determined in duplicate in a liquid scintillation 
counter (Beckman LS3801). 
Addition of Radio labeled GM1 Fifty micromoles 3H-GM3 was 
added to cultures on days 2 and 4 as above. At the time of harvesting 
for cell counting, keratinocyte gangliosides were extracted as de-
scribed previously [6] and separated on HPTLC plates. Control 
plates 'Were run to identify gangliosides with resorcinol spraying 
and gangliosides GM3 , GM2 , GMI , and GDJ were applied as standards. 
The bands of GM3 were scraped after exposure to the x-ray film, 
dissolved in chloroform: methanol 2: 1, and centrifuged. Superna-
tants 'With ganglioside and collected culture media were analyzed 
for radioactivity by scintillation counting. 
RESULTS 
Effect of Ganglioside Addition on Proliferation Previous 
experiments have demonstrated that GM3 is the major ganglioside of 
keratinocytes in vivo (6]; GMt' GD3 , DDh' and GDtb are also present 
in smaller amounts. Recently, 9-0-acetyl-GD3 was shown to be a 
significant ganglioside of basal carcinoma cells [6] . As a result of 
these findings, these gangliosides as well as sialic acid were selected 
to be added to cultured keratinocytes. Owing to the very limited 
quantities of purified GDJ and 9-0-acetyl-GDJ, we were only able to 
study the effects of these gangliosides in undifferentiated keratino-
cytes. 
G M3 , GD3 , 9-0-acetyl-GD3 , and GDlb inhibited proliferation of 
keratinocytes grown in 0.15 mM Ca++ in the range of 10-100 JIM 
(Fig la), with inhibition by 9-0-acetyl-Go3 > GM3 > GDJ > GOlb . 
In contrast, GMt' GOh ' and sialic acid were not significantly inhibi-
tory although, of these, GOh showed the greatest inhibitory effect. 
Time-course studies showed maximal inhibition 2 d after the addi-
tion of G M3 . When cells that had been inhibited by treatment with 
GM3 for 72 h were washed and incubated without GM3 , recovery 
through proliferation was noted within 72 h (Table I). 
G M3 also inhibited proliferation of keratinocytes grown in 
1.5 ruM Ca++ (Fig Ib), the SCC-12F2 cell line (Fig le; inhibition of 
proliferation of the SCC-12B2 cell line was similar), and the SCC-
13 cell line (Fig Id). In studies on all of these cells, GMt was only 
slightly inhibitory at 50 and 100 JIM concentrations, although 
greater inhibition was noted in the SCC-13 line. Ichthyotic and 
psoriatic keratinocytes were slightly more sensitive than normal 
keratinocytes to the inhibitory effects (38.58 ± 9.41 % of control 
and 37.07 ± 5.29% of control at 50 JIM GM3 , respectively; control 
numbers of cells from patients with psori.asis, N = 10, were 8.94 X 
106 + 0 .66 X 106 cells). Confluent keratl110cytes were less sensitive 
Table I. Keratinocyte Recovery Following 
72 h of Treatment with 50 JIM GM3 
Treatment of Cells 
No GMJ 
No recovery 
12 h recovery 
24 h recovery 
48 h recovery 
72 h recovery 
Number of Cells ± SD 
2.57 ± 0.29 X 105 
1.63 ± 0.20 X 105 
1.78 ± 0.19 X 105 
2.02 ± 0.37 X 105 
2.21 ± 0.43 X 105 
2.85 ± 0.26 X 105 
GMJ INHIBITS KERATINOCYTE PROLrFERATION 843 
Table II. Content of Ganglioside in Cells Treated and 
Untreated with 3H-GM3 (ug sialic acid/ lOS cells) 
Untreated 50J1,M 3H-GM 3 
GM3 90 153 
X· 11 11 
G03 27 27 
Others 17 17 
• Based on HPTLC migration. X migrates between GM1 and GMJ • 
than keratinocytes grown to a pre-confluent state (59.65 ± 6.49% 
of control at 50 JIM GM3 versus 42.5 ± 6.69% of control in pre-
confluent KCs). The inhibition of confluent cells may reflect cell 
toxicity, because confluent cells are not proliferating; however, the 
number of viable keratinocytes following treatment with all gangli-
osides and with sialic acid was always at least 75-90% of control 
viability, with no relationship noted between concentration and 
toxicity. 
Effect of Added Ganglioside on Differentiation Light micro-
scopic examination of cells treated with GM:I did not reveal gross 
morphologic changes of differentiation. However, with concentra-
tions of GM3 of 50 JIM and 100 JIM increased dendricity and elonga-
tion of 3 - 5% of cells was noted. These elongated cells excluded 
trypan blue dye. The percentage of cells with cornified envelopes 
was not altered by treatment with GM3 (9.18 ± 2.36% with 50 JIM 
GM3 versus 7.34 ± 1.98% without GM3 in 0.15 mM Ca++; 86.82 ± 
9.43% versus 84.63 ± 8.65% in 1.5 mM Ca++) , and staining of 
keratinocytes with anti-desmoplakin and anti-involucrin antibodies 
at both low calcium and high calcium concentration was also un-
changed by treatment with GM3 . In keratinocytes cultured in KGM 
with 0.07 ~ ~a++, anti-desmoplakin antibody bound to the per-
1I1uclear regIOn In a spotty pattern without deposition at areas of 
c~ll-ce!1 contact, r.egardless of whether cells were exposed to GM3. 
LikeWise, III keratlllocytes grown in KGM with 1.5 mM Ca++, the 
antibodies bound intensely along the periphery of cells at sites of 
cell-cell co~tact, regardless of whether cultured in the presence of 
GM3 · Keratl110cytes treated and untreated with 50 JIM GM3 exhib-
ited no difference in the staining patterns with anti-involucrin anti-
body, sJ~owing in~reased numbers of cells with intense cytoplasmic 
and peripheral stalI1111g with anti-involucrin antibodies in 1.5 mM 
Ca++ KGM. 
Ganglioside Incorporation into Keratinocytes Following 
treatment of keratinocytes in 0.15 mM Ca++ with 3H-GM3 
(189,000 cpm/Jimol), incorporation into extracted membrane was 
only noted in the ganglioside band that migrated with the GM3 s~andard. No radioactivity was detected in non-ganglioside frac-
tions. 0.585 ± 0.015% of the labeled GM3 (153.2 Jig sialic acid/ lOS 
cells) incorporated into the membrane. Since the total amount of 
gangliosi?e in .undifferentiated keratinocytes is approximatel,Y 
150 Jig Sialic aCid/lOS cells, of which 60% is GM3 (901lg sialic 
acid/lOS cells), the content of GM3 is less than 1.7 times that of 
untreated cells when 50 JIM GM3 is added (Table II); membrane flux 
with replacement of unlabeled by labeled GM3 could further lower 
the amount of increase in GM3 content following supplementation. 
~he amount of the other major keratinocyte gangliosides remained 
Virtually unchanged after GM3 addition. 
DISCUSSION 
Modulation of cell proliferation by glycolipids has been addressed 
by the addition of purified glycolipids to cultured cells. Exoge-
nously added GM3 has been shown to inhibit proliferation in cu lture 
[3,21 - 24) of a variety of normal cells and cell lines, suggesting that 
GM3 may function ill 1Ii1)O as a modulator of cellular proliferation. 
Furthermore, modified forms of GM3 may inhibit or stimulate cell 
proliferation. LysO-GM3 (without the fatty acy l chain) also inhibits 
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growth of A431 cells [25,26], whereas an analogue of GM3 (de-N-
acetyl-GM3) may encourage proliferation [26]. 
We have previously shown that GM3 is the predominant ganglio-
side of human epidermis [6]. The overall content of GM3 , however, 
is only 0.065% of the total lipid of epidermis, an amount that would 
be more consistent with a role as a regulatory membrane component 
than as a structural one. Anti-GM3 antibody binding to human stra-
tum corneum is strong in normal skin, but deficient or absent in a 
variety of hyperproliferative disorders, including psoriasis, hyper-
proliferative forms of ichthyosis, squamous cell carcinoma, and the 
cornoid lamellae of porokeratosis [7]. Furthermore, alterations in 
the total content of ganglioside and also of 9-0-acetyl-GO) in basal 
cell carcinomas [6] further suggest that GM3 and other related gangli-
osides may participate in regulation of cell growth. 
In this study, we cu ltured keratinocytes in defined KGM medium 
without serum and without a feeder layer of fibroblasts, because we 
have found significant amounts of ganglioside in fetal calf serum 
(l.4l1g GM3/ml serum) versus in KGM with bovine pituitary ex-
tract (0.00625I1g GM3/ml, unpublished data), and because GM3 is 
the predominant ganglioside of cultured fibroblasts [27]. In this 
report, we have found rhat supplemental GM3 inhibits proliferation 
of cultured normal keratinocytes, keratinocytes from patients with 
hyperproliferative disorders of epidermis, and cutaneous SCC lines. 
The inhibition is dose dependent and is not associated with signifi-
cant cell toxicity as determined by ttypan blue exclusion. Our stud-
ies on cell recovery further suggest that GM3 inhibits keratinocyte 
proliferation in a reversible manner, although we cannot distin-
guish from these studies if all cells or merely a subpopulation of cells 
are recovering. 
Previous studies have suggested a correlation of increased GM3 
and cell differentiation. Undifferentiated "crypt" cells of intestinal 
epithelia have lactosylceramide (the asialo form of GM3), but no GM3 
or GM3 synthetase [28]. With transformation to villus cells, high 
levels of GM3 and GM3 synthetase are found, with a low content of 
lactosylceramide. Supplemental gangliosides have been shown to 
induce neurite outgrowth in neuroblastoma cells, a phenomenon 
associated with neuronal differentiation [29,31]. In addition, GM3 
has previously been shown to induce "differentiation" into specific 
differentiation pathways of human leukemic cell lines [23,32]. 
Keratinocyte differentiation was not induced by adding GM3 , as 
demonstrated by similarities in cornified envelope production and 
in expression of desmoplakin and involucrin in treated and un-
treated cells. Although growth arrest of keratinocytes often occurs 
as a consequence ofkeratinocyte differentiation, decreased prolifera-
tion does not necessarily result in the onset of differentiation. Iso-
leucine starvation or ethionine supplementation, for example, re-
sults in reversible inhibition of proliferation in the GI phase of the 
cell cycle without associated increased keratinocyte differentiation 
[33 - 35]. Recently TGF-fJ has also been shown to reversibly inhibit 
keratinocyte growth without increasing involucrin expression or 
cell envelope formation [34,36]. 
Ganglioside synthesis follows two major pathways, with GM3 as a 
substrate [6,37] . In one pathway, GM3 may be sialylated by sialyl-
transferase-II (ST -II) to form GO), which may be reversibly acety-
lated at the 9-0-acyl position to form 9-0-acetyl-Go3 . GO) may also 
be conjugated with N-acetylgalactose and subsequently with galac-
tose to form GOlh ("b" pathway). Alternatively, GM3 may be conju-
gated with N-acetylgalactose by the action of N-acetylgalactosa-
minyltransferase (GaINAcT) and subsequently with galactose to 
form GMI , which may be further sialylated to form GOIa ("a" path-
way). It is intriguing to note that the inhibitory gangliosides all 
derive from the "b" pathway, whereas the gangliosides without 
effect are part of the "a" pathway. The shift from synthesis of "b" 
pathway to "a" pathway gangliosides has been shown to depend 
directly on the activities ofST-II and GalNAcT enzymes [38-40]. 
Our results suggest that the enzymes that synthesize and metabolize 
keratinocyte gangliosides and thus regulate the relative concentra-
tions of membrane gangliosides may participate in regulating prolif-
eration by balancing the amounts of GM3 , GO), 9-0-acetyl-GO), and 
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GOlb ' Similarly, an altered content of gangliosides has been asso-
ciated with decreased proliferation in intestinal mucosal cells [28] 
and in neuronal cells [411. In addition, shifts in synthesis from gang-
lio- to lacto- to globo-series glycolipids has been noted with mye-
loid cell differentiation [42]. 
To effect the inhibition, GM3 concentrations of 10-100 11M are 
required. Although the pharmacologic effect is quite significant, 
the amount of ganglioside in the medium when 50 11M GM3 is added 
is, by calculation, more than 300 times that in the keratinocyte cell 
membrane. Other investigators have proposed that supplemental 
gangliosides modulate proliferation by incorporation into the cell 
membrane, the lipid moiety being inserted into the lipid layer 
[43,44]. We have demonstrated that 50 11M 3H-GM3 incorporates 
into cells as GM3 at an amount that is only 1.7 times that of the 
normal cellular content of GM3 , without consideration of replace-
ment of unlabeled GM3 by radiolabeled GM3 . In our studies, supple-
mental 3H-GM3 was not detectably metabolized during the time 
course of the experiments, suggesting that the inhibitory effect is 
most likely due directly to "b" pathway ganglioside inhibition. 
The mechanism of inhibition of keratinocyte proliferation by 
gangliosides is unknown, although inhibition of phosphorylation 
of growth factor receptors, especially epidermal growth factor and 
fibroblast growth factor receptors, has resulted from the addition of 
GM3 to other cells [4,21,45]. Studies of the effect of keratinocyte 
gangliosides on proliferation and of the interaction of gangliosides 
with keratinocyte growth factors and receptors may promote better 
understanding of the regulation of keratinocyte proliferation. Re-
cently, administration anti-ganglioside antibodies has resulted in 
tumor regression ill vivo of melanomas (anti-GO) [46,47] and anti-
GM3 lactone [48]) and of neuroblastomas (anti-Go2 [49]). Ganglio-
sides and anti-ganglioside antibodies may prove to be new means of 
therapy for hyperproliferative and neoplastic cutaneous disorders. 
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